Authority control databases
| International | |
|---|---|
| National | |
| Academics | |
| Other | |
Rodolphe Barrangou | |
|---|---|
| Alma mater | |
| Scientific career | |
| Institutions | |
Rodolphe Barrangou is the Todd R. Klaenhammer Distinguished Professor in Probiotics Research in the Department of Food, Bioprocessing and Nutrition Sciences at North Carolina State University; Co-Founder and Chief Executive Officer of CRISPR Biotechnologies; Co-Founder and Chief Scientific Officer of Ancilia Biosciences; Co-Founder, President and Chief Scientific Officer of TreeCo; and Co-Founder and member of the Scientific Advisory Board of Intellia Therapeutics. His research focuses on CRISPR-Cas9 in bacteria.[1]
In 2017, Barrangou was named[2] Editor-in-Chief of The CRISPR Journal, a peer-reviewed journal covering the field of genome editing and CRISPR research, which debuted in February 2018.
He was elected as a member into the National Academy of Sciences in 2018.[3] He was also elected into the National Academy of Engineering in 2019 for the discovery of CRISPR-Cas genome editing and engineering microbes, plants, and animals for food and other applications.
Dr Barrangou's research has been funded by the National Institutes of Health, National Science Foundation, US Department of Agriculture, and institutional grants.[4] He previously worked as an Adjunct Professor of Food Science at Pennsylvania State University, and R&D Director of Genomics at DuPont.
In 2007, Barrangou was the first author on a paper published in Science providing experimental proof for the immune function of CRISPR.[5] He has worked with Jennifer Doudna on Cas9 guided RNA characterization. He has been awarded 17 patents as of 2016.[4]
